Eli Lilly announced a $4.5 billion investment in two manufacturing sites in Lebanon, Indiana, bringing total Indiana commitments since 2020 to over $21 billion.
Lilly Lebanon Advanced Therapies, the company's first dedicated genetic medicine manufacturing facility, opened on May 6 to support clinical and commercial genetic modalities.
Lilly Lebanon API site, slated to open in 2027, will be the largest API production site in U.S. history.
Facilities will produce Foundayo (orforglipron), Zepbound/Mounjaro (tirzepatide), and investigational retatrutide.
Investment driven by evolving pipeline and demand; Lilly anchors Indiana's LEAP District, boosting local economy.